4MB.F ALPHAHELIX MOL.DIAGN. SK1

Healthcare Biotechnology Frankfurt Exchange
0.0100 EUR
Close of Nov 11, 2026
0.0035 0.0315
Market cap
EUR 684K
P/E
1.0x
P/B
1.13x
ROE
119.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 4MB.F undervalued?

Graham number

The Graham number of ALPHAHELIX MOL.DIAGN. SK1 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALPHAHELIX MOL.DIAGN. SK1 fundamental analysis

No fundamental analysis for ALPHAHELIX MOL.DIAGN. SK1 yet.

ALPHAHELIX MOL.DIAGN. SK1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALPHAHELIX MOL.DIAGN. SK1

Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquarte…

Full company profile